Non-histone substrates of histone deacetylases as potential therapeutic targets in epilepsy. (2nd January 2021)

• Record Type: Journal Article
• Authors: Kumar, Sonali; Attrish, Diksha; Srivastava, Arpna; Banerjee, Jyotirmoy; Tripathi, Manjari; Chandra, P Sarat; Dixit, Aparna Banerjee
• Is Part Of: Expert opinion on therapeutic targets. Volume 25:Number 1(2021)
• Page Start: 75
• Page End: 85
• Publication Date: 2021-01-02
• Subjects: Antiepileptic drugs -- epilepsy -- epileptogenesis -- histone deacetylase (HDAC) -- HDAC inhibitor -- seizure; Drugs -- Research -- Periodicals; 615.072
• DOI: 10.1080/14728222.2021.1860016
• Languages: English
• ISSNs: 1744-7631

Abstract

ABSTRACT: Introduction : Epilepsy is a network-level neurological disorder characterized by unprovoked recurrent seizures and associated comorbidities. Aberrant activity and localization of histone deacetylases (HDACs) have been reported in epilepsy and HDAC inhibitors (HDACi) have been used for therapeutic purposes. Several non-histone targets of HDACs have been recognized whose reversible acetylation can modulate protein functions and can contribute to disease pathology. Areas covered : This review provides an overview of HDACs in epilepsy and reflects its action on non-histone substrates involved in the pathogenesis of epilepsy and explores the effectiveness of HDACi as anti-epileptic drugs (AEDs). It also covers the efforts undertaken to target the interaction of HDACs with their substrates. We have further discussed non-deacetylase activity possessed by specific HDACs that might be essential in unraveling the molecular mechanism underlying the disease. For this purpose, relevant literature from 1996 to 2020 was derived from PubMed. Expert opinion : The interaction of HDACs and their non-histone substrates can serve as a promising therapeutic target for epilepsy. Pan-HDACi offers limited benefits to the epileptic patients. Thus, identification of novel targets of HDACs contributing to the disease and designing inhibitors targeting these complexes would be more effective and holds a greater potential as an anti-epileptogenic therapy.